Abeona Therapeutics Inc Dossier - Source-backed chat

Abeona Therapeutics Inc

ABEONASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.21

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $5.25Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $300.2M

Enterprise Value $259M

Shares Outstanding 57.9M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Abeona Therapeutics has successfully transitioned from a clinical-stage R&D biotech to a commercial-stage enterprise following the landmark FDA approval of ZEVASKYN (pz-cel) in April 2025. ZEVASKYN is the first and only autologous cell-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa (RDEB). With a list price of $3.1 million, the therapy represents a highly differentiated, potentially curative one-time surgical option compared to chronic, weekly topical alternatives. Early commercial traction is evident, with Q1 2026 net product revenue reaching $8.7 million from three treated patients, and the Qualified Treatment Center (QTC) network expanding to six major sites. Backed by a robust cash position of $168.3 million as of March 31, 2026 (bolstered by the $155 million sale of its Priority Review Voucher in 2025), Abeona is well-funded to execute its commercial blueprint and target monthly profitability starting in mid-2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$14.00

Mean target$19.71

High · most bullish analyst$28.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.3120%

Commercial launch is hampered by complex surgical logistics, slow patient identification, or manufacturing bottlenecks. High SG&A expenses and cash burn persist, delaying the path to profitability and forcing dilutive capital raises. Payer pushback or gross-to-net discounts compress margins.

Base CaseCentral scenario

$19.7150%

Matches the consensus mean

Steady scaling of ZEVASKYN treatments with a gradual expansion of the QTC network. Revenue grows in line with consensus estimates, reaching approximately $65.5 million in 2026. The company manages its commercial SG&A expenses effectively, achieving monthly profitability in late 2026 or early 2027 while maintaining a strong cash runway.

Bull CaseUpside scenario

$28.0030%

Rapid commercial adoption of ZEVASKYN driven by swift QTC onboarding and high biopsy-to-treatment conversion rates. The company achieves sustained monthly profitability ahead of schedule, and successfully advances its newly in-licensed engineered T-cell therapy (ABO-701) for solid tumors, unlocking a high-value oncology pipeline.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class autologous cell-based gene therapy (ZEVASKYN) approved for a high-unmet-need rare disease (RDEB).
Strong clinical differentiation as a potentially curative, durable one-time surgical graft compared to chronic weekly topical treatments.
Robust balance sheet with $168.3 million in cash and short-term investments as of Q1 2026, providing a multi-year runway.
Established commercial infrastructure with published coverage policies now in place for 95% of commercially insured U.S. lives.

Key Investment Risks

Execution and operational risks associated with scaling a complex, short-shelf-life (84 hours) autologous cell therapy.
High commercial SG&A expenses and cash burn rate ($23.1 million in Q1 2026) that could delay profitability.
Dependence on a small pool of specialized Qualified Treatment Centers and a limited patient population for near-term revenue.

Thesis Invalidation Triggers

Failure to achieve monthly profitability by the end of FY2026.
Severe manufacturing failures or contamination issues leading to product release delays.
Significant loss of commercial insurance coverage or restrictive reimbursement policies.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.